The U.S. government just ended decades of legal gridlock between strict federal drug prohibition and the 40 states running active medical cannabis programs. Acting Attorney General Todd Blanche signed a historic order on Thursday, April 23, 2026, reclassifying authorized medical marijuana products. They drop from Schedule I down to Schedule III under the Controlled Substances Act.
This sweeping policy shift resolves a massive bureaucratic backlog. President Donald Trump signed a December 2025 executive order demanding the Justice Department rapidly expedite the rescheduling process to ease business regulations and boost research. The DOJ followed through today.
The federal government treated all marijuana exactly like heroin and LSD for nearly 90 years. Schedule I status meant the drug legally had no accepted medical use. The new rule changes that entirely for patients and state-licensed operators. We are seeing a massive shift in how federal agencies handle previously restricted compounds, similar to changing perspectives on therapeutic peptides.
The action provides the historical background and details of a December 2025 executive order that expedited this final rulemaking process. Acting Attorney General Todd Blanche signed the formal Schedule III reclassification order on April 23, 2026, triggering immediate business tax implications. The exact DOJ policy shift is narrow. It applies specifically to FDA-approved and state-licensed marijuana products. The order explicitly notes that unauthorized forms of marijuana remain strictly prohibited as Schedule I substances.
How Schedule III Status Changes Clinical Research and Dispensary Taxes
State-licensed medical operators and clinical researchers are the primary beneficiaries here. Moving these products to Schedule III establishes regulatory parity with substances like ketamine and anabolic steroids. This dismantles the primary federal roadblock preventing widespread, authorized clinical research and human trials on cannabis.
Dispensaries also get a massive financial win. The Schedule III shift removes the infamous IRS Section 280E tax penalty. Cannabis businesses can now finally deduct standard business expenses on their federal taxes. Opposition groups are fighting back. Smart Approaches to Marijuana, led by Kevin Sabet, heavily criticized the move. They argue the federal government is commercializing addiction.